Related Experiment Video
Updated: May 23, 2025
An Optimized Hemagglutination Inhibition HI Assay to Quantify Influenza-specific Antibody Titers
Published on: December 1, 2017
Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness in Germany-Data From Primary Care and
Annika Erdwiens1, Carolin Hackmann1, Marianne Wedde2
1Department 3 Infectious Disease Epidemiology, Unit 36 Respiratory Infections, Robert Koch Institute, Berlin, Germany.
Abstract:
Between October 2024 and February 2025, influenza A(H1N1)pdm09 initially predominated in Germany, with subsequent co-circulation of influenza B/Victoria. We provide interim estimates of 2024/2025 influenza vaccine effectiveness (VE) in Germany across primary care and secondary care. VE against any influenza in primary care was 31% (95% CI: 1-52). Interim VE was high against influenza B; however, interim estimations indicated a much lower VE against influenza A especially in the adult age group below 60 years. In secondary care, VE against any influenza was 69% (95% CI: 21-88). Our findings support promoting influenza vaccination alongside infection-preventing behavior and prompt antiviral therapy.
More Related Videos
12:09Measuring Influenza Neutralizing Antibody Responses to AH3N2 Viruses in Human Sera by Microneutralization Assays Using MDCK-SIAT1 Cells
Published on: November 22, 2017
08:52Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes
Published on: July 26, 2019
